Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Cellectis is implementing good security practices.
Read more about the latest issues in cybersecurity
Biometrics is the technical term for body measurements and calculations, and human characteristics. ...
An exploit is a piece of software, data or sequence of commands that takes advantage of a ...
Compare Cellectis's security performance with other companies